Pfizer Advances HYMPAVZI After Successful Hemophilia Trial Results

Pfizer Inc. (NYSE:PFE) ranks among the best set-it-and-forget-it stocks to buy. On June 26, Pfizer Inc. (NYSE:PFE) declared that the Phase 3 BASIS research results showed that its medication HYMPAVZI (marstacimab) was superior to other inhibitors in treating hemophilia A or B patients.

Pfizer Advances HYMPAVZI After Successful Hemophilia Trial Results

Pixabay/Public Domain

Comparing HYMPAVZI to on-demand treatment, the trial revealed that the former decreased the annualized bleeding rate by 93%. A pre-filled pen was used to administer HYMPAVZI once weekly via subcutaneous injection, requiring little preparation. During the study, no thromboembolic events or deaths were reported, indicating that the medication was generally well tolerated.

Pfizer Inc. (NYSE:PFE) intends to present the data to regulatory bodies in order to start the regulatory filing process for HYMPAVZI in hemophilia patients with inhibitors. The medication has already been approved by regulators in the United States and Europe for use in hemophilia patients without inhibitors.

Pfizer Inc. (NYSE:PFE) is a leading global pharmaceutical company that develops, produces, and sells biopharmaceutical medicines worldwide.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.